Description: Indexed universal life (IUL) continues to be the most popular universal life (UL) product with sales reaching $1B in Q4 2023, according to LIMRA. There is little long term experience for IUL and many companies value and model IUL just like UL, but there are material potential differences that need to be considered for valuation and projection purposes. Presenters will discuss key risks and differences between IUL and UL relating to policyholder behavior and how to value, project, monitor and manage those risks to avoid repeating misestimates of the past. Presenters will also discuss broader life assumption risks such as mortality and yearly renewable term (YRT) reinsurance risk. Attendees will learn about options on how to potentially address underperforming blocks of IUL and will obtain an improved perspective on the risks of IUL products and the differences versus UL and how to incorporate these differences into their valuation and projection exercises.

Description: The report discusses using behavioral science in redesigning life insurance underwriting questionnaires to improve disclosure rates. It includes an experimental study, industry survey insights, and discussions on application forms, behavioral science application, and organizational engagement with behavioral science in the insurance industry.

Description: The SOA’s Committee on Life Insurance Company Expenses (CLICE) has submitted its recommendation for the 2024 Generally Recognized Expense Table (GRET) for use with individual life insurance sales illustrations.

Description: There are many underwriting issues being discussed in states that challenge how information is used in the underwriting process. Learn more about a variety of rules and regulations, including Colorado's proposed regulation requiring a governance and risk management framework for life insurance carriers' use of external consumer data and information sources, as well as algorithms and predictive models using such data. Recent proposals are more far-reaching than existing requirements in states that have put up guardrails for the use of new data sets and algorithms, especially for underwriting. Listen in as experts discuss the potential issues and implications of this and other proposed regulations.

Description: Go over how the actuarial processes have changed over the past 10+ years with the move to PBR, US GAAP LDTI, IFRS 17 and other emerging requirements.

Description: Large SEC US GAAP filers implemented LDTI 1/1/2023. Other insurance companies have until 1/1/2025. Learn more about those companies with a 2025 implementation date. What do these companies need to know? What can be learned from the 2023 implementers? What are the biggest hurtles to implementation?

Description: Mortality improvement assumptions have typically been focused on all-cause mortality improvement. However, as evidenced in recent years, the cause of death has a large impact on mortality improvement. Join our panel of experts as they discuss mortality improvement through the lens of different causes of death. This discussion will include a review of the historical cause specific mortality improvement trends seen in the U.S. population and how this relates to the insured population. The panelists will then discuss how to use these trends to inform future mortality improvement assumptions. Key learning objectives include: - Identifying the trends in mortality improvement for select causes of death - Understanding how to adapt these for an insured population - Applying these learnings to mortality improvement assumptions

Description: Much has been published about the increased financial statement volatility under U.S. GAAP Long Duration Targeted Improvements (LDTI). Discover more about tools and techniques that actuaries and other financial reporting professionals can use to reduce volatility risk and understand the relationships between certain risks and volatility. By attending the session, you will learn to identify sources of financial statement volatility under LDTI and methods to manage or reduce the volatility.

Description: Recommendation for a set of improvement factors to be used in conjunction with the 2008 Valuation Basic table or the 2015 Valuation Basic table

Description: This research report examines the ban of the use of genetic testing information in life insurance mortality.